Having trouble accessing articles? Reset your cache.

Hybrigenics escape route

Proteomics company Hybrigenics S.A. last week said it divested two of its three discovery programs to focus on bringing ubiquitin-specific protease inhibitors into clinical development for cancer. The company will continue developing an in-licensed vitamin D analog for prostate cancer, which is in Phase I trials, but otherwise will focus its efforts entirely on USP inhibitors.

Read the full 568 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers